ECSP024369A - S-metil-dihidro-ziprasidona para el tratamiento de trastornos psiquiatricos y oculares - Google Patents

S-metil-dihidro-ziprasidona para el tratamiento de trastornos psiquiatricos y oculares

Info

Publication number
ECSP024369A
ECSP024369A EC2002004369A ECSP024369A ECSP024369A EC SP024369 A ECSP024369 A EC SP024369A EC 2002004369 A EC2002004369 A EC 2002004369A EC SP024369 A ECSP024369 A EC SP024369A EC SP024369 A ECSP024369 A EC SP024369A
Authority
EC
Ecuador
Prior art keywords
disorders
disorder
dementias
treatment
behavioral
Prior art date
Application number
EC2002004369A
Other languages
English (en)
Spanish (es)
Inventor
Chandra Aggarwal Prakash
Teresa Annette Smolarek
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26903852&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP024369(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ECSP024369A publication Critical patent/ECSP024369A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
EC2002004369A 2000-06-02 2002-11-29 S-metil-dihidro-ziprasidona para el tratamiento de trastornos psiquiatricos y oculares ECSP024369A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20913600P 2000-06-02 2000-06-02
US21217200P 2000-06-16 2000-06-16

Publications (1)

Publication Number Publication Date
ECSP024369A true ECSP024369A (es) 2003-02-06

Family

ID=26903852

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2002004369A ECSP024369A (es) 2000-06-02 2002-11-29 S-metil-dihidro-ziprasidona para el tratamiento de trastornos psiquiatricos y oculares

Country Status (44)

Country Link
US (1) US20060287336A1 (ja)
EP (3) EP1286672B1 (ja)
JP (2) JP2003534381A (ja)
KR (1) KR20030007824A (ja)
CN (1) CN1431901A (ja)
AP (2) AP1831A (ja)
AR (1) AR028937A1 (ja)
AT (3) ATE345818T1 (ja)
AU (1) AU2001258690A1 (ja)
BG (1) BG107267A (ja)
BR (1) BR0111271A (ja)
CA (1) CA2410618A1 (ja)
CY (1) CY1105992T1 (ja)
CZ (1) CZ20023860A3 (ja)
DE (3) DE60133596D1 (ja)
DK (1) DK1468686T3 (ja)
DO (1) DOP2001000181A (ja)
EA (1) EA007068B1 (ja)
EC (1) ECSP024369A (ja)
EE (1) EE200200670A (ja)
ES (1) ES2277170T3 (ja)
GE (1) GEP20053512B (ja)
HN (1) HN2001000119A (ja)
HR (1) HRP20020953A2 (ja)
HU (1) HUP0301747A2 (ja)
IL (2) IL152782A0 (ja)
IS (1) IS6619A (ja)
MA (1) MA26908A1 (ja)
MX (1) MXPA02011862A (ja)
NO (1) NO325077B1 (ja)
NZ (1) NZ551012A (ja)
OA (1) OA12267A (ja)
PA (1) PA8518301A1 (ja)
PE (1) PE20011329A1 (ja)
PL (1) PL365576A1 (ja)
PT (2) PT1468686E (ja)
SI (1) SI1468686T1 (ja)
SK (1) SK16622002A3 (ja)
SV (1) SV2002000473A (ja)
UA (1) UA79425C2 (ja)
UY (1) UY26742A1 (ja)
WO (1) WO2001091756A2 (ja)
YU (1) YU90702A (ja)
ZA (1) ZA200209665B (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7419493B2 (en) 2002-12-13 2008-09-02 Regents Of The University Of Minnesota Scleral depressor
US7667037B2 (en) 2003-10-24 2010-02-23 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
ES2250001B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.
JP2012174228A (ja) * 2011-02-24 2012-09-10 Kyocera Corp プログラム保護装置および通信装置
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9981041B2 (en) * 2016-08-23 2018-05-29 Ira Jason Salzman Ophthalmic lubricating spray

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997042190A1 (en) * 1996-05-07 1997-11-13 Pfizer Inc. Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (=ziprasidone), its preparation and its use as dopamine d2 antagonist
TW491847B (en) * 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
EP0985414B1 (en) * 1998-05-26 2003-08-27 Pfizer Products Inc. Medicament for the treatment of glaucoma and ischemic retinopathy
EP1165083A2 (en) * 1999-04-06 2002-01-02 Sepracor Inc. Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites

Also Published As

Publication number Publication date
EP1468686B1 (en) 2006-11-22
ATE345818T1 (de) 2006-12-15
EA200201168A1 (ru) 2003-06-26
UA79425C2 (en) 2007-06-25
AP1747A (en) 2007-05-31
CY1105992T1 (el) 2011-04-06
EP1698338B1 (en) 2008-04-09
PT1698338E (pt) 2008-06-03
EE200200670A (et) 2004-08-16
SI1468686T1 (sl) 2007-04-30
MXPA02011862A (es) 2003-04-10
US20060287336A1 (en) 2006-12-21
DK1468686T3 (da) 2007-03-12
OA12267A (en) 2004-01-20
EP1698338A2 (en) 2006-09-06
AP2005003272A0 (en) 2005-03-31
WO2001091756A3 (en) 2002-09-26
ES2277170T3 (es) 2007-07-01
JP2008056700A (ja) 2008-03-13
SK16622002A3 (sk) 2004-07-07
EP1286672A2 (en) 2003-03-05
ATE391507T1 (de) 2008-04-15
PT1468686E (pt) 2007-01-31
DE60124093D1 (de) 2006-12-07
UY26742A1 (es) 2001-12-28
NO20025760L (no) 2003-01-15
NO20025760D0 (no) 2002-11-29
EP1698338A3 (en) 2006-09-20
MA26908A1 (fr) 2004-12-20
CA2410618A1 (en) 2001-12-06
AP1831A (en) 2008-02-26
PE20011329A1 (es) 2002-01-15
NZ551012A (en) 2008-04-30
ATE343387T1 (de) 2006-11-15
AR028937A1 (es) 2003-05-28
ZA200209665B (en) 2003-11-28
WO2001091756A2 (en) 2001-12-06
HN2001000119A (es) 2001-09-11
DE60133596D1 (de) 2008-05-21
PL365576A1 (en) 2005-01-10
BR0111271A (pt) 2003-06-10
KR20030007824A (ko) 2003-01-23
HRP20020953A2 (en) 2005-02-28
EP1468686A2 (en) 2004-10-20
YU90702A (sh) 2005-11-28
EP1286672B1 (en) 2006-10-25
JP2003534381A (ja) 2003-11-18
DE60124791D1 (de) 2007-01-04
DE60124791T2 (de) 2007-09-13
IL152782A0 (en) 2003-06-24
IS6619A (is) 2002-11-14
EP1468686A3 (en) 2004-12-01
AU2001258690A1 (en) 2001-12-11
PA8518301A1 (es) 2002-09-17
EA007068B1 (ru) 2006-06-30
NO325077B1 (no) 2008-01-28
SV2002000473A (es) 2002-10-24
IL152782A (en) 2007-10-31
DOP2001000181A (es) 2002-04-15
GEP20053512B (en) 2005-05-10
BG107267A (bg) 2003-06-30
HUP0301747A2 (hu) 2003-09-29
CN1431901A (zh) 2003-07-23
CZ20023860A3 (cs) 2004-01-14

Similar Documents

Publication Publication Date Title
ECSP088593A (es) 5-(arilsulfonil)-pirazolopiperidinas
CO5611138A2 (es) Composicion de ziprasidona y controles sinteticos
PA8593101A1 (es) Composiciones para el tratamiento de crecimiento celular anormal
CR11095A (es) Compuestos amino-heterociclicos
NI200700270A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
ECSP056192A (es) 3-fluoro-piperidinas como antagonistas de nmda/nr2b
UY30058A1 (es) (indazol-5-il)-piracinas y (1,3-dihidro-indol-2-on)-piracinas para el tratamiento de enfermedades y afecciones mediadas por la rho quinasa
CO6321153A2 (es) Derivados de cromeno y cromano y sus usos
ECSP055719A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
BRPI0406879A (pt) Dispositivo de liberação sustentada e método para a liberação ocular de agentes adrenérgicos
UY29924A1 (es) Medicamentos en base a 11-(4-(2-(2-hidroxietoxi)etil)-1-piperazinil)dibenzo-(b,f)(1,4)tiazepina y sus sales farmacéuticamente aceptables
ES2183583T3 (es) Agente con efecto antidepresivo, que contiene pramipexol y sertralina.
AR057887A1 (es) Composiciones y metodos de tratamiento de trastornos del snc
UY28400A1 (es) Metabolito
BRPI0721113A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para prevenir, tratar ou melhorar doenças ou condições dérmicas ou distúrbios
AR034396A1 (es) Compuestos 4-(1r-4-piperidilen)-4h-benzo[4,5]ciclohepta[1,2]-tiofeno-1-a y sus isomeros opticamente activos, un metodo para su sintesis y el uso de dichos compuestos para la manufactura de un medicamento
AR038483A1 (es) Derivados de quinazolinona, un proceso para su produccion, composiciones farmaceuticas y el uso de los mismos para la fabricacion de un medicamento como agonistas canabinoides
AR028705A1 (es) Bis-arilsulfonas
ECSP024369A (es) S-metil-dihidro-ziprasidona para el tratamiento de trastornos psiquiatricos y oculares
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
GT200200275A (es) Derivados de ester del acido pirrolidina-2-carboxilico
AR049343A1 (es) Derivados tioeter, su obtencion y utilizacion de los mismos como agentes farmaceuticos
AR056056A1 (es) Asociacion entre la agomelatina y un inhibidor de la recaptacion de la noradrenalina y las composiciones farmaceuticas que las contienen
UY28401A1 (es) Metabolito
CL2009001377A1 (es) Compuestos derivados de 3-azabiciclo[3.1.0]hexano; procedimiento de preparacion; compuestos intermediarios; composiciones farmaceuticas que los contienen, utiles en el tratamiento de trastornos del sueno, del humor, enfermedad del alzheimer, apatia y/o estados depresivos, entre otros.